Tradipitant is under clinical development by Vanda Pharmaceuticals and currently in Phase III for Gastroparesis. According to GlobalData, Phase III drugs for Gastroparesis have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

Tradipitant is under clinical development by Vanda Pharmaceuticals and currently in Phase III for Motion Sickness. According to GlobalData, Phase III drugs for Motion Sickness does not have sufficient historical data to build an indication benchmark PTSR for Phase III.

Tradipitant (VLY-686 or LY686017) is an experimental drug that is a neurokinin 1 antagonist. It works by blocking substance P, a small signaling molecule. Originally, this compound was owned by Eli Lilly and named LY686017.

Drowsiness, dry mouth, and constipation are common adverse effects.

Promising investigational pharmacologic therapies include relamorelin, prucalopride, and aprepitant. A novel endoscopic therapy is gastric peroral endoscopic pyloromyotomy, which is associated with improved gastric emptying.

Metoclopramide: This medicine increases the movements in your digestive system, helping the food to pass through more quickly and efficiently. This is the only medication in the United States that is FDA approved to treat gastroparesis. However, in some patients it may cause movement disorders.

That said, many studies show that as a whole, Dramamine is more effective at preventing motion sickness, though it is less convenient given the dosing. Another option is scopolamine, which is commonly known as the round patch placed behind one's ear.

Scopolamine is most commonly used as a transdermal patch that is applied behind the ear for up to 72 hours, at which point it can be replaced. Transdermal scopolamine is the most effective pharmaceutical for the prevention and treatment of motion sickness. The patch should be applied 4 hours prior to departure.

Metoclopramide: This medicine increases the movements in your digestive system, helping the food to pass through more quickly and efficiently. This is the only medication in the United States that is FDA approved to treat gastroparesis.

G-POEM stands for gastric peroral endoscopic myotomy. It is an innovative procedure to treat patients with gastroparesis, a condition where the stomach does not empty properly.

About Tradipitant Tradipitant is a neurokinin-1 receptor antagonist licensed by Vanda from Eli Lilly and Company. Tradipitant is currently in clinical development for gastroparesis and motion sickness. The FDA has imposed a partial clinical hold on tradipitant clinical protocols of longer than 12 weeks duration.

The majority of patients remaining on treatment experienced an improvement in symptoms of gastroparesis, particularly postprandial fullness, nausea, vomiting, and stomach fullness. Thus, domperidone treatment is beneficial for many patients with symptoms of gastroparesis.